Global to push GA events into
skip to main content

Title: New multifunctional ligands for potential use in the design therapeutic or diagnostic radiopharmaceutical imaging agents

A class of diagnostic and therapeutic compounds are derived from phosphinimines that include ligands containing either a single phosphinimine functionality or both a phosphinimine group and a phosphine or arsine group, or an aminato group, or a second phosphinimine moiety. These phosphinimine ligands are complexed to early transition metal radionuclides (e.g., {sup 99m}Tc or {sup 186}Re/{sup 188}Re) or late transition metals (e.g., {sup 105}Rh or {sup 109}Pd). The complexes with these metals {sup 186}Re/{sup 188}Re, {sup 99m}Tc and {sup 109}Pd exhibit a high in vitro and high in vivo stability. The complexes are formed in high yields and can be neutral or charged. These ligands can also be used to form stable compounds with paramagnetic transition metals (e.g., Fe and Mn) for potential use as MRI contrast agents. Applications for the use of ligands and making the ligands are also disclosed.
Inventors:
; ; ;
Issue Date:
OSTI Identifier:
441867
Assignee:
Univ. of Missouri, Columbia, MO (United States) PTO; SCA: 550601; PA: INS-97:004436; EDB-97:044591; SN: 97001739262
Patent Number(s):
US 5,601,800/A/
Application Number:
PAN: 8-211,905
Contract Number:
FG02-89ER60875
Resource Relation:
Other Information: PBD: 11 Feb 1997
Research Org:
University of Missouri
Country of Publication:
United States
Language:
English
Subject:
55 BIOLOGY AND MEDICINE, BASIC STUDIES; RADIOPHARMACEUTICALS; CHEMICAL PREPARATION; DIAGNOSTIC USES; THERAPEUTIC USES; TECHNETIUM 99; ISOMERIC NUCLEI; RHENIUM 186; RHENIUM 188; RHODIUM 105; PALLADIUM 109